Additionally, cancer treatments can lead to alterations in insulin sensitivity, endothelial damage, lipid metabolism, hormone deficiencies, and obesity, all metabolic dysfunctions that contribute to developing metabolic syndrome [14]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.